Fly News Breaks for March 3, 2020
Mar 3, 2020 | 10:34 EDT
Piper Sandler analyst Joseph Catanzaro tells investors in a research note that Ocular Therapeutix provided additional data for OTX-TKI as part of its corporate presentation that he thinks points to very favorable early activity, saying the inserts appear to be well-tolerated and predictable with the insert resorbing consistently at 9-10 months. Catanzaro says the update was a very positive early look for OTX-TKI and the hydrogel platform in retinal diseases that could provide significant upside to his current model assumptions. He keeps an Overweight rating and $7 price target on the shares.
News For OCUL From the Last 2 Days
There are no results for your query OCUL